Critical Pharmaceuticals is managed by a team of industry experienced scientific professionals. Commercial strategy is directed by a Board of Directors of international standing and with a broad base of expertise, while scientific direction comes from a pool of world renowned excellence.
Lisbeth Illum, PhD
Chief Executive Officer
Lisbeth Illum was the founder and for 12 years the Managing Director of DanBioSyst UK Ltd. and for 3 years the Managing Director of Phaeton Research Ltd. both companies that specialised in Drug Delivery Systems. She is also associated with Nottingham University as a Special Professor. She was awarded her M. Pharm, Ph. D and D.Sc. from the Royal Danish School of Pharmacy in 1972, 1978 and 1988, respectively. She is a world renowned scientist in the field of novel drug delivery systems for difficult drugs such as peptide and proteins. She has published more than 300 scientific papers (is among the top 100 most cited scientists on pharmacology) and has co-edited four books including "Peptide Drug Delivery Systems" published by Plenum Press, 1986. She has filed nearly fifty patents on novel drug delivery systems. She has been awarded the title of "Docent" in the Royal Danish School of Pharmacy and has been the recipient of several scientific awards. She has been elected a Fellow of the AAPS and is the Vice-President of the CRS. She has lectured throughout the world at conferences and workshops. She is on the Editorial Boards of seven scientific journals. She joins Critical Pharmaceutical as the CEO on her extensive business and managing experience from running small drug delivery companies.
Professor Steve Howdle, PhD
Chief Scientific Officer
Steve is a founder and chief scientific officer of Critical Pharmaceuticals. Steve is a world renowned scientist in the field of supercritical fluid processing with over 15 years experience in the field. Steve holds a Chair at the University of Nottingham and over the past 10 years his research has focused on the pharmaceutical formulation of drugs using supercritical fluids. He has received the Corday Morgan Medal and Award (2001) and Interdisciplinary Award (2005) of the RSC, the Jerwood Salters Environment Award (2001), Royal Society/Wolfson Research Merit Award (2003) and the DECHEMA-Award 2006 of the Max Buchner Research Foundation. Steve is responsible for directing the company towards developing drug delivery products, finding new partners and investment.
Alan Baines
Financial Director
Alan is a Chartered Accountant and has over 25 years experience in working with business start ups. Alan was Senior Partner in an internationally renowned business development firm and he was the author of his firm's standard publication on the subject. Alan has a clear appreciation of the problems and changes faced by growing businesses and his experience in the subject has helped many companies identify, anticipate and solve such critical issues. As Financial Director he is responsible for all issues relating to finance, tax and internal control.
The Board of Directors
Martyn Davies, PhD
Professor Davies is a world-renowned expert in the field of controlled release drug delivery. He is Chairman and co-founder of Molecular Profiles (spin off from Nottingham University Pharmacy School) and has a personal chair of Biomedical Surfaces Chemistry in Nottingham University. He is Scientific Secretary of the Controlled Release Society, Fellow of the RPSGB, RSC, and American Institute of Medical and Biological Engineering.
Nikin Patel, PhD
Non-Executive Director
Dr Patel is CEO of Molecular Profiles and has significant expertise in the application of surface chemistry tools for studying pharmaceutical formulations. He has successfully led the growth of Molecular Profiles since 1997 to become a global leader of specialist analytical services for the pharmaceutical industry.
Mike Healy, PhD
Dr Michael A Healy is the Director of Business Administration at the School of Chemistry, University of Nottingham, and is the University' s appointed Director for Critical Pharmaceuticals.
David Gough
Mr Gough is an entrepreneur specialising in biomedical and other technology-based businesses. In the past ten years he has founded or co-founded 6 companies one of which (Vectura Group plc) has been successfully floated on AIM. Mr Gough has over 30 years of experience as a senior manager, consultant, entrepreneur and investor and has raised, or helped to raise, close to £100m in equity capital and VC funds. Mr Gough has extensive board experience involving some 20 companies and has worked for or consulted to many of the world's leading pharma, healthcare and biotech companies.
The Scientific Advisory Board
Critical Pharmaceuticals has appointed a Scientific Advisory Board with outstanding credentials in the pharmaceutical and biotechnology sectors.
Derek Riley
Derek is a senior pharmaceutical executive with extensive global experience in pharmaceutical research and development, regulatory compliance, quality assurance, quality control and facilities qualification / validation. Derek is on the Register of Qualified Persons under EEC Directives 75/319/EEC and 81/851/EEC and has successfully implemented regulatory compliance and quality assurance programmes for Sterling Winthrop, RP Scherer and Cardinal Health over a 35 year period, latterly as Corporate Vice President, Quality.
Andrew Burgess
Andrew is a Chemical and Bio Process Engineer who has been working in the field of Supercritical Fluids for over 10 years. During this time Andrew has been involved in scaling up lab scale supercritical process to the industrial scale including the world's first Supercritical Fluid reaction plant and the largest Supercritical water oxidation plant to be operated o a production scale. Andrew brings CPL extensive knowledge on the operation; scale-up and development of Supercritical processes.
|
